Ki-67 immunohistochemical expression in mandibular ameloblastoma: A prognostic indicator for local recurrence

Ayman Hegab, Mohmmad Shuman, Mohammed Abd El-Akher, Delaram Arwlan

Medcal City Teaching Hospital, Teaching Laboratory, Baghdad, Iraq.
Oral and Maxillofacial Surgery, Faculty of Dental Medicine, Al-Azhar University, Assuit, Egypt.
Oral and Maxillofacial Surgery, Faculty of Dental Medicine, Al-Azhar University, Cairo, Egypt.

DOI: 10.4236/ojst.2013.39086                

Abstract

Objective: This study used Ki-67 to evaluate the proliferative activity of ameloblastoma in an attempt to provide a scientific basis for any differences in the biologic behaviour that exists between the different types of ameloblastoma and correlate the results with the recurrence rate. Study design: We assessed Ki-67 expression by immunohistochemistry in 32 cases of mandibular ameloblastoma. Formalin-fixed, paraffinembedded blocks were sectioned and used for Haematoxylin & Eosin (H&E) staining. H&E slides were used to re-evaluate the histological types of the ameloblastoma. Immunohistochemical analysis for Ki-67 with a labelled streptavidin-biotin-peroxidase complex technique was performed on tumour sections using Monoclonal Mouse Anti-Human Ki-67 Antigen (clones MIB1, code M7240, Dako Corporation). Lymph nodes (lymphoma) were used as positive control for Ki-67. Results: The specimens comprised 18 cases of Follicular ameloblastoma, 7 cases of Cystic ameloblastoma, 4 cases of plexiform ameloblastoma, and 3 cases of Acanthotic ameloblastoma. The results showed that cellular proliferative activity varied within the ameloblastoma types. There was no statistically significant difference in the Ki-67 Acanthotic, cystic and follicular types of ameloblastoma, while plexiform type showed statistically significantly higher levels than the other 3 types. The mean Ki-67 labelling index of plexiform ameloblastoma ranged from 13 to 30 with a mean of 19.75. The mean values of Ki-67 were statistically significantly higher in recurrent than non-recurrent cases. Conclusion: The significant expression of Ki-67 could provide useful prognostic markers for proliferative activity and good prognostic indicators for recurrence rate of mandibular ameloblastoma.

Keywords

Mandibular Ameloblastoma; Recurrence; Immunohistochemistry; Ki-67

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	Barnes, L., Eveson, J.W., Reichart, P. and Sidransky, D., (2005) World Health Organization classification of tumours: Pathology and genetics head and neck tumours. International Agency for Research on Cancer Press, Lyon.
[2]	Kramer, I.R.H.P.J. and Shear, M. (1992) Histological typing of odontogenic tumours. 2nd Edition, Springer-Verlag, Berlin, 11-14. http://dx.doi.org/10.1007/978-3-662-02858-2_3
[3]	Li, T.J., Wu, Y.T., Yu, S.F. and Yu, G.Y. (2000) Unicystic ameloblastoma: A clinicopathologic study of 33 Chinese patients. American Journal of Surgical Pathology, 24, 1385-1392. http://dx.doi.org/10.1097/00000478-200010000-00008
[4]	Gardner, D.G. (1996) Some current concepts on the pathology of ameloblastomas. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology, 82, 660-669. http://dx.doi.org/10.1016/S1079-2104(96)80441-0
[5]	Li, T.-J., Browne, R.M. and Matthews, J.B. (1995) Expression of proliferating cell nuclear antigen (PCNA) and Ki-67 in unicystic ameloblastoma. Histopathology, 26, 219-228. http://dx.doi.org/10.1111/j.1365-2559.1995.tb01435.x
[6]	Slootweg, P.J. (1995) p53 protein and Ki-67 reactivity in epithelial odontogenic lesions: An immunohistochemical study. Journal of Oral Pathology & Medicine, 24, 393-397. http://dx.doi.org/10.1111/j.1600-0714.1995.tb01207.x
[7]	Tilakaratne, W., Odell, E., Lock, C., Morgan, P. (1999) Cell proliferation in odontogenic tumors [abstract]. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology, 88, 210.
[8]	Tsai, S.T. and Jin, Y.T. (1995) Proliferating cell nuclear antigen (PCNA) expression in oral squamous cell carcinomas. Journal of Oral Pathology & Medicine, 24, 313-315. http://dx.doi.org/10.1111/j.1600-0714.1995.tb01191.x
[9]	Van Diest, P.J., Brugal, G., Baak, J.P.A. (1998) Proliferation markers in tumours: Interpretation and clinical value. Journal of Clinical Pathology, 51, 716-724. http://dx.doi.org/10.1136/jcp.51.10.716
[10]	Gerdes, J., Becker, M.H.G., Key G, et al. (1992) Immunohistological detection of tumour growth fraction (Ki-67 antigen) in formalin-fixed and routinely processed tissues [letter]. Journal of Pathology, 174, 1685-1687.
[11]	Guillaud, P., de Manoir, S. and Geigneurin, D. (1989) Quantification and topographical description of Ki-67 antibody labelling during the cell cycle of normal fibroblastic (MRC-5) and mammary tumour cell lines (MCF-7). Analytical Cellular Pathology, 1, 25-39.
[12]	di Vinci, A., Geido, E., Pfeffer, U., et al. (1993) Quantitative analysis of mitotic and early-G1 cells using monoclonal antibodies against the AF-2 protein. Cytometry, 14, 421-427. http://dx.doi.org/10.1002/cyto.990140411
[13]	Isola, J.J., Helin, H.J., Helle, M.J., et al. (1990) Evaluation of cell proliferation in breast carcinoma. Comparison of Ki-67 immunohistochemical study, DNA flow cytometric analysis, and mitotic count. Cancer, 65, 1180-1184. http://dx.doi.org/10.1002/1097-0142(19900301)65:5<1180::AID-CNCR2820650525>3.0.CO;2-7
[14]	Barnard, N.J., Hall, P.A., Lemoine, N.R., et al. (1987) Proliferative index in breast carcinoma determined in situ by Ki67 immunostaining and its relationship to clinical and pathological variables. Journal of Pathology, 152, 287-295.
[15]	Gerdes, J., Becker, M.H.G., Key, G., et al. (1992) Immunohistological detection of tumour growth fraction (Ki-67 antigen) in formalin-fixed and routinely processed tissues [letter]. Journal of Pathology, 174, 1685-1687.
[16]	Wintzer, H.O., Zipfel, I., Schulte-Moenting, J., et al. (1991) Ki67 immunostaining in human breast tumors and its relationship to prognosis. Cancer, 67, 421-428. http://dx.doi.org/10.1002/1097-0142(19910115)67:2<421::AID-CNCR2820670217>3.0.CO;2-Q
[17]	Veronese, S.M., Gambacorta, M., Gottardi, O., et al. (1993) Proliferation index as a prognostic marker in breast cancer. Cancer, 71, 3926-3931. http://dx.doi.org/10.1002/1097-0142(19930615)71:12<3926::AID-CNCR2820711221>3.0.CO;2-2
[18]	Robinson, L. and Martinez, M.G. (1977) Unicystic ameloblastoma: A prognostically distinct entity. Cancer, 40, 2278. http://dx.doi.org/10.1002/1097-0142(197711)40:5<2278::AID-CNCR2820400539>3.0.CO;2-L
[19]	Philipsen, H.P. and Reichert, P.A. (1998) Unicystic ameloblastoma. A review of 193 cases from the literature. Oral Oncology, 34, 317. http://dx.doi.org/10.1016/S1368-8375(98)00012-8
[20]	Gardner, D.G. and Pecak, A.M. (1980) The treatment of ameloblastoma based on pathologic and anatomic princeples. Cancer, 46, 2514-2519. http://dx.doi.org/10.1002/1097-0142(19801201)46:11<2514::AID-CNCR2820461133>3.0.CO;2-9
[21]	Blazi, M., Ninu, B.M., Becciolin1, A., et al. (1991) Labelling index in squamous cell carcinoma of the larynx. Head & Neck, 13, 344-348. http://dx.doi.org/10.1002/hed.2880130413
[22]	Bouzubar, N., Walker, K.J., Griffith, K., et al. (1989) Ki-67 immunostaining in primary breast cancer; pathological and clinical associations. British Journal of Cancer, 59, 943-945. http://dx.doi.org/10.1038/bjc.1989.200
[23]	Brown, D.C. and Gatter, K.C (1990) Monoclonal antibody Ki-67: its use in histopathology. Histopathology, 17, 489-503. http://dx.doi.org/10.1111/j.1365-2559.1990.tb00788.x
[24]	Chaurel, P., Courdi, A., Gioanni, J., Vallicion, J., Santini, J. and Demard, E. (1989) The labelling index: A prognostic factor in head and neck carcinoma. Radiotherapy & Oncology, 14, 231-237. http://dx.doi.org/10.1016/0167-8140(89)90171-0
[25]	Brown, D.C. and Gatter, K.C. (1990) Monoclonal antibody Ki-67: Its use in histopathology. Histopathology, 17, 489-503. http://dx.doi.org/10.1111/j.1365-2559.1990.tb00788.x
[26]	Brown, D.C. and Gatter, K.C. (2002) Ki67 protein: The immaculate deception? Histopathology, 40, 2-11. http://dx.doi.org/10.1046/j.1365-2559.2002.01343.x
[27]	Li, T.-J., Browne, R.M. and Matthews, J.B. (1995) Expression of proliferating cell nuclear antigen (PCNA) and Ki-67 in unicystic ameloblastoma. Histopathology, 26, 219-228. http://dx.doi.org/10.1111/j.1365-2559.1995.tb01435.x
[28]	Van Oijen, M.G.C.T., Medema, R.H., Slootweg, P.J. and Rijksen, G. (1998) Positivity of the proliferation marker Ki-67 in noncycling cells. American Journal of Clinical Pathology, 110, 24-31.
[29]	Rudolph, P., Peters, J., Lorenz, D., Schmidt, D. and Parwaresch, R. (1998) Correlation between mitotic and Ki67 labeling indices in paraffin-embedded carcinoma specimens. Human Pathology, 29, 1216-1222. http://dx.doi.org/10.1016/S0046-8177(98)90248-9
[30]	Li, Y., Han, B. and Li, L.-J. (2012) Prognostic and proliferative evaluation of ameloblastoma based on radiographic boundary. International Journal of Oral Science, 4, 30-33. http://dx.doi.org/10.1038/ijos.2012.8
[31]	Florescu, A., Simionescu, C., Ciurea, R. and Pitru, A. (2012) P53, Bcl-2 and Ki67 immunoexpression infollicular solid ameloblastomas. Romanian Journal of Morphology and Embryology, 53, 105-109.
[32]	Kumamoto, H., Izutsu, T., Ohki, K., Takahashi, N. and Ooya, K. (2004) p53 gene status and expression of p53, MDM2, and p14 proteins in ameloblastomas. Journal of Oral Pathology & Medicine, 33, 292-299. http://dx.doi.org/10.1111/j.0904-2512.2004.00044.x
[33]	Gadbail, A.R., Patil, R. and Chaudhary, M. (2012) Coexpression of Ki-67and p53 protein in ameloblastoma and keratocysticodontogenic tumor. Acta Odontologica Scandinavica, 70, pp. 529-535.
[34]	de Vicente, J.C., Torre-Iturraspe, A., Gutiérrez, A.M. and Lequerica-Fernández, P. (2010) Immunohistochemical comparative study of the odontogenic keratocysts and other odontogenic lesions. Medicina Oral Patologia Oral y Cirugia Bucal, 15, e709-e715. http://dx.doi.org/10.4317/medoral.15.e709
[35]	Pietilainen, T., Lipponen, P., Aaltomaa, S., et al. (1996) The important prognostic value of Ki-67 expression as determined by image analysis in breast cancer. Journal of Cancer Research and Clinical Oncology, 122, 687-692. http://dx.doi.org/10.1007/BF01209033
[36]	Pinder, S.E., Wencyk, P., Sibbering, D.M., et al. (1995) Assessment of the new proliferation marker MIB1 in breast carcinoma using image analysis: Associations with other prognostic factors and survival. British Journal of Cancer, 71, 1546-1549. http://dx.doi.org/10.1038/bjc.1995.30